Parkinson Disease, Multiple System Atrophy, Rapid Eye Movement Sleep Behavior Disorder, Normal Pressure Hydrocephalus
Conditions
Keywords
Alpha-synuclein
Brief summary
This will be an observational study looking at clinical and biomarker characteristics in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Rapid Eye Movement Sleep Behavior Disorder (RBD), Normal Pressure Hydrocephalus and matched controls. Saliva, plasma, serum, urine, and cerebrospinal fluid (CSF) samples will be collected from participants.
Detailed description
This is an observational study looking at clinical and biomarker characteristics in patients with Parkinson's disease (PD), Multiple System Atrophy (MSA), Rapid Eye Movement Sleep Behavior Disorder (RBD), Normal Pressure Hydrocephalus (NPH) and matched controls. Saliva, plasma, serum, urine, and cerebrospinal fluid samples will be collected from participants. Samples will be assessed for levels of misfolded alpha-synuclein aggregates. Clinical characteristics will also be assessed. Misfolded alpha-synuclein aggregates have the potential to serve as an early biomarker for PD and MSA, increasing the ability to diagnose and treat individuals with these diseases earlier. This study examines the effectiveness of using a novel technique for distinguishing between different parkinsonian disorders by measuring small misfolded α-synuclein aggregates in different biofluids.
Interventions
OTHERBiomarker assay
Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
Sponsors
Stony Brook University
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
For PD subjects: Inclusion Criteria: 1. Age 50-75 2. Diagnosis of idiopathic PD as confirmed by a movement disorder specialist 3. Age of onset of motor symptoms between 50 - 75 4. Well-established response to dopaminergic agents and/or amantadine 5. Ability to complete questionnaires 6. Ability to provide informed consent 7. Willingness to go off parkinsonian medication for 12 hours prior to off assessment 8. Medical record includes a brain MRI taken within the past 12 months showing no evidence of a tumor or abscess
Exclusion criteria
1. Symptomatic (secondary) parkinsonism (ie. drug induced) 2. Atypical parkinsonian variants 3. History of cancer (except basal or squamous cell skin cancer) within 5 years 4. Known liver disease 5. Hematological disorders 6. History of stereotactic or ablative brain surgery 7. Treatment with an investigational drug or device within the last 30 days 8. Pregnancy 9. Inability to comply with or tolerate study procedures 10. Conditions precluding the safe performance of lumbar puncture (LP): use of anticoagulants and hematologic abnormalities (INR\>1.3;platelet count \<80,000) MSA Subjects: Inclusion Criteria: 1. Age 50-75 2. Age of onset of motor symptoms between 50-75 3. Diagnosis of probable or possible MSA as confirmed by a movement disorders specialist 4. Ability to complete questionnaires 5. Ability to provide informed consent 6. Willingness to go off parkinsonian medications for 12 hours prior to off assessment 7. Medical record indicates a brain MRI taken within the past 12 months showing no evidence of a tumor or abscess
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare levels of misfolded alpha-synuclein aggregates in participants with PD, MSA, RBD, NPH and controls | 3 weeks | Levels of misfolded alpha-synuclein in CSF, serum, plasma, saliva, and urine will be quantified using the protein misfolding cyclic amplification (PMCA) technology |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Investigate the relationship between levels of misfolded alpha-synuclein aggregates and disease severity in PD and MSA | 3 weeks | Levels of misfolded alpha-synuclein aggregates will be quantified using the PMCA technology. PD and MSA disease severity will be assessed using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the Unified Multiple System Atrophy Rating Scale (UMSARS), respectively. All groups will receive the MDS-UPDRS III and the RBD Questionnaire. |
| Investigate the relationship between levels of misfolded alpha-synuclein aggregates across different biofluid reservoirs, including CSF, serum, plasma, saliva, and urine | 3 weeks | Levels of misfolded alpha-synuclein in the different biofluid reservoirs will be quantified using the PMCA technology |
Countries
United States
Outcome results
None listed